Satavaptan Dose-Ranging Study in Normonatraemic Patients With Cirrhotic Ascites (Normo~CAT)

This study has been completed.
Information provided by:
Sanofi Identifier:
First received: July 13, 2007
Last updated: NA
Last verified: July 2007
History: No changes posted

The primary objective is to determine the optimal dose or range of doses of SR121463B for the treatment of ascites when used concomitantly with a standard dose regimen of spironolactone and furosemide.

The secondary objective is to determine the tolerability of different fixed doses of SR121463B over a 14 day treatment period in cirrhotic ascites.

Condition Intervention Phase
Liver Cirrhosis
Drug: satavaptan (SR121463B)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: SR121463B in Cirrhotic Ascites Treatment With Normonatraemia: A Placebo-Controlled, Dose-Comparison Study

Resource links provided by NLM:

Further study details as provided by Sanofi:

Primary Outcome Measures:
  • Change in body weight [ Time Frame: within 14 days ]

Secondary Outcome Measures:
  • Abdominal girth and discomfort [ Time Frame: 14 days ]
  • Paracentesis [ Time Frame: 14 days ]
  • Quality of life [ Time Frame: 14 days ]

Enrollment: 148
Study Start Date: April 2004
Study Completion Date: January 2005

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cirrhosis of the liver confirmed by ultrasound, endoscopic examination or biochemical evidence
  • Moderate or tense ascites
  • Serum sodium of >130 mmol/l.

The above information is not intended to contain all considerations relevant to a patient’s potential participation in a clinical trial.

  Contacts and Locations
Please refer to this study by its identifier: NCT00501566

Sanofi-Aventis Administrative Office
Buenos Aires, Argentina
Australia, New South Wales
Sanofi-Aventis Administrative Office
Cove, New South Wales, Australia
Sanofi-Aventis Administrative Office
Diegem, Belgium
Canada, Quebec
Sanofi-Aventis Administrative Office
Laval, Quebec, Canada
Sanofi-Aventis Administrative Office
Zagreb, Croatia
Czech Republic
Sanofi-Aventis Administrative Office
Praha, Czech Republic
Sanofi-Aventis Administrative Office
Paris, France
Sanofi-Aventis Administrative Office
Berlin, Germany
Sanofi-Aventis Administrative Office
Budapest, Hungary
Sanofi-Aventis Administrative Office
Milan, Italy
Sanofi-Aventis Administrative Office
Bucuresti, Romania
Sanofi-Aventis Administrative Office
Barcelona, Spain
Sponsors and Collaborators
  More Information

Additional Information:
No publications provided Identifier: NCT00501566     History of Changes
Other Study ID Numbers: DFI5563, SR121463
Study First Received: July 13, 2007
Last Updated: July 13, 2007
Health Authority: Spain: Spanish Agency of Medicines
Romania: National Medicines Agency
Croatia: Ministry of Health and Social Care
United States: Food and Drug Administration

Keywords provided by Sanofi:
cirrhotic ascites

Additional relevant MeSH terms:
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases processed this record on April 17, 2014